Black Diamond Therapeutics (NASDAQ: BDTX) is a clinical-stage oncology company that discovers and develops small-molecule precision medicines targeting genetically defined cancers. The company generates no product revenue, funding operations through equity issuances and investment income while advancing a pipeline of drug candidates through clinical trials. BDTX's lead program is silevertinib, a small-molecule inhibitor being evaluated in a Phase 1 trial for patients with relapsed/recurrent glioblastoma (GBM) carrying EGFR alterations. As of the 10-K filed March 16, 2026, the company presented Phase 1 clinical data for silevertinib at multiple conferences in 2024 and 2025, including ASCO, EANO, SNO, and AACR, demonstrating central nervous system tissue penetration and EGFR signaling suppression in patient tumors. BDTX relies on third-party contract manufacturers to produce its drug candidates and must comply with FDA current Good Manufacturing Practice regulations. The company has no commercial products and carries a cash-funded balance sheet typical of pre-revenue biotechnology firms.

Revenue model

No product revenue as of FY2025. Operations are funded through proceeds from equity issuances, including common stock offerings and employee stock purchase plan exercises, and returns from an investment portfolio. The cash flow statement for the year ended December 31, 2025 shows net cash provided by operating activities and investing activities driven by investment maturities and sales, not product sales.

Products and services

Silevertinib: a small-molecule EGFR inhibitor in Phase 1 clinical trials for relapsed/recurrent glioblastoma with EGFR alterations and/or fusions. Clinical data presented at ASCO Annual Meeting (Q2 2024), EANO, SNO, and AACR (2024-2025) demonstrated tumor tissue penetration and EGFR signaling suppression. No approved or commercialized products as of the 10-K filed March 16, 2026.

Customers and end markets

End market is oncology, specifically patients with genetically defined cancers including glioblastoma with EGFR alterations. Clinical trial participants are enrolled through investigator-sponsored and company-sponsored trials. No commercial customers as of the filing date.

Value-chain role

Drug discovery and clinical development. BDTX designs small-molecule precision medicine candidates and advances them through Phase 1 trials. Manufacturing is outsourced to third-party contract manufacturers subject to FDA cGMP requirements. The company does not manufacture, distribute, or sell commercial products.

Geographic exposure

Operates under FDA oversight in the United States as the primary regulatory authority. Subject to EU Clinical Trials Regulation and EMA oversight for any EU-based trial activity. Also subject to MHRA jurisdiction in the United Kingdom following implementation of the Windsor Framework on January 1, 2025. Clinical trial activity referenced at U.S. and European conferences.

Source: SEC 10-K, filed 2026-03-16

Industry: Biological Products, (No Diagnostic Substances) Peers: Mink Therapeutics Inc Harvard Apparatus Regenerative Technology Inc Cyteir Therapeutics, Inc. Genprex Inc iBio Inc Passage Bio Inc TCR2 THERAPEUTICS INC. Taysha Gene Therapies Inc